| 國立成功大學 |
2017 |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Abou-Alfa, G.K.;Yen, C.-J.;Hsu, C.-H.;O’Donoghue, J.;Beylergil, V.;Ruan, S.;Pandit-Taskar, N.;Gansukh, B.;Lyashchenko, S.K.;Ma, J.;Wan, P.;Shao, Y.-Y.;Lin, Z.-Z.;Frenette, C.;O’Neil, B.;Schwartz, L.;Smith-Jones, P.M.;Ohtomo, T.;Tanaka, Tanaka T.;Morikawa, H.;Maki, Y.;Ohishi, N.;Chen, Y.-C.;Agajanov, T.;Boisserie, F.;Di, Laurenzio L.;Lee, R.;Larson, S.M.;Cheng, A.-L.;Carrasquilo, J.A. |
